Potential contributions of intimal and plaque hypoxia to atherosclerosis

Current Atherosclerosis Reports

Volumn 17, Issue 6, 2015, Pages 1-10

  Fong, Guo Hua ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Angiogenesis; Atherosclerosis; Hypoxia; Inflammation; Intima; Vasa vasorum

Indexed keywords

ANGIOGENESIS INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; SAPONIN; THALIDOMIDE; TNF 470; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL POPULATION; HUMAN; HYPOXIA; LEUKOCYTE; MACROPHAGE; MICROVASCULATURE; MONOCYTE; OXIDATIVE PHOSPHORYLATION; OXYGENATION; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; VACCINATION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; ANIMAL; FOAM CELL; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; FOAM CELLS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR;

EID: 84928346704     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-015-0510-0     Document Type: Review

References (86)

1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26. doi:10.1056/NEJM199901143400207.
2. Lusis AJ. Atheroscler Nat. 2000;407(6801):233–41. doi:10.1038/35025203.
3. Ao M, Miyauchi M, Inubushi T, et al. Infection with Porphyromonas gingivalis exacerbates endothelial injury in obese mice. PLoS One. 2014;9(10):e110519. doi:10.1371/journal.pone.0110519.
4. Ismail A, Khosravi H, Olson H. The role of infection in atherosclerosis and coronary artery disease: a new therapeutic target. Heart Dis. 1999;1(4):233–40.
5. Galkina E, Ley K. Leukocyte influx in atherosclerosis. Curr Drug Targets. 2007;8(12):1239–48.
6. Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis—a double-edged sword. Ann Med. 2008;40(8):606–21. doi:10.1080/07853890802186913.
7. Abbas A, Aukrust P, Russell D, et al. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One. 2014;9(1):e84935. doi:10.1371/journal.pone.0084935.
8. Gao L, Chen Q, Zhou X, Fan L. The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol. 2012;65(10):872–6. doi:10.1136/jclinpath-2012-200828.
9. Moreno PR, Purushothaman M, Purushothaman KR. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Ann N Y Acad Sci. 2012;1254:7–17. doi:10.1111/j.1749-6632.2012.06497.x.
10. Subbotin VM. Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis. Theor Biol Med Model. 2012;9:11. doi:10.1186/1742-4682-9-11. This article prevents a novel hypothesis, accompanied with data and illustration, which argue that angiogenesis in the outer intimal tissues, is a critical requirement which allows the entry of oxLDL particles into arterial vascular wall tissues. This hypothesis contrasts the traditional concept that oxLDL enter the vascular wall through injured arterial vascular endothelium. The concept that angiogenesis controls the initiation of atherosclerotic development may lead to the identification of new therapeutic targets for the prevention and treatment of atherosclerosis.
11. Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63(1):1–11. doi:10.1016/j.jacc.2013.09.019.
12. Parathath S, Yang Y, Mick S, Fisher EA. Hypoxia in murine atherosclerotic plaques and its adverse effects on macrophages. Trends Cardiovasc Med. 2013;23(3):80–4. doi:10.1016/j.tcm.2012.09.004.
13. Hulten LM, Levin M. The role of hypoxia in atherosclerosis. Curr Opin Lipidol. 2009;20(5):409–14. doi:10.1097/MOL.0b013e3283307be8.
14. Hutter R, Speidl WS, Valdiviezo C, et al. Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1alpha activation: a novel aspect of angiogenesis in atherosclerosis. J Cardiovasc Transl Res. 2013;6(4):558–69. doi:10.1007/s12265-013-9469-9.
15. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–66. doi:10.1161/CIRCRESAHA.114.302721.
16. Sims FH. The initiation of intimal thickening in human arteries. Pathology. 2000;32(3):171–5.
17. Jeziorska M, Woolley DE. Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development. Hum Pathol. 1999;30(8):919–25.
18. Ho-Tin-Noe B, Le Dall J, Gomez D, et al. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ Res. 2011;109(9):1003–14. doi:10.1161/CIRCRESAHA.110.235390.
19. Gossl M, Herrmann J, Tang H, et al. Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Res Cardiol. 2009;104(6):695–706. doi:10.1007/s00395-009-0036-0.
20. Sluimer JC, Gasc JM, van Wanroij JL, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51(13):1258–65. doi:10.1016/j.jacc.2007.12.025.
21. Parathath S, Mick SL, Feig JE, et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res. 2011;109(10):1141–52. doi:10.1161/CIRCRESAHA.111.246363.
22. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res. 2009;104(2):210–8. doi:10.1161/CIRCRESAHA.108.181040. 221p following 218.
23. Vink A, Schoneveld AH, Lamers D, et al. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis. 2007;195(2):e69–75. doi:10.1016/j.atherosclerosis.2007.05.026.
24. Nishi K, Oda T, Takabuchi S, et al. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal. 2008;10(5):983–95. doi:10.1089/ars.2007.1825.
25. Marsch E, Theelen TL, Demandt JA, et al. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis. Arterioscler Thromb Vasc Biol. 2014;34(12):2545–53. doi:10.1161/ATVBAHA.114.304023. This article demonstrates that hypoxia may be indeed a contributing factor to the development atherosclerosis, whereas improved oxygenation reduces the development of atherosclerotic plaque lesions.
26. Nakano D, Hayashi T, Tazawa N, et al. Chronic hypoxia accelerates the progression of atherosclerosis in apolipoprotein E-knockout mice. Hypertens Res. 2005;28(10):837–45. doi:10.1291/hypres.28.837.
27. Ramkhelawon B, Yang Y, van Gils JM, et al. Hypoxia induces netrin-1 and Unc5b in atherosclerotic plaques: mechanism for macrophage retention and survival. Arterioscler Thromb Vasc Biol. 2013;33(6):1180–8. doi:10.1161/ATVBAHA.112.301008. This article presents data that hypoxia may promote the inflammatory responses in atherosclerotic plaque lesion by promoting the expression of macrophage retention proteins, thus keeping macrophages in plaque tissues where they contribute to further plaque growth.
28. Marsch E, Sluimer JC, Daemen MJ. Hypoxia in atherosclerosis and inflammation. Curr Opin Lipidol. 2013;24(5):393–400. doi:10.1097/MOL.0b013e32836484a4.
29. Arnaud C, Poulain L, Levy P, Dematteis M. Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice. Atherosclerosis. 2011;219(2):425–31. doi:10.1016/j.atherosclerosis.2011.07.122.
30. Sergin I, Evans TD, Bhattacharya S, Razani B. Hypoxia in plaque macrophages: a new danger signal for interleukin-1beta activation? Circ Res. 2014;115(10):817–20. doi:10.1161/CIRCRESAHA.114.305197.
31. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2003;10(2):63–71.
32. Fukuchi M, Watanabe J, Kumagai K, et al. Normal and oxidized low density lipoproteins accumulate deep in physiologically thickened intima of human coronary arteries. Lab Invest. 2002;82(10):1437–47.
33. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007;27(5):1159–65. doi:10.1161/ATVBAHA.106.134080.
34. Sho M, Sho E, Singh TM, et al. Subnormal shear stress-induced intimal thickening requires medial smooth muscle cell proliferation and migration. Exp Mol Pathol. 2002;72(2):150–60. doi:10.1006/exmp.2002.2426.
35. Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol. 2014;9(2):142–60. doi:10.1007/s11481-014-9531-7.
36. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157(1):111–7 e112. doi:10.1016/j.ahj.2008.08.010.
37. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225–8. doi:10.1016/j.jacc.2005.07.006.
38. Jun J, Reinke C, Bedja D, et al. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2010;209(2):381–6. doi:10.1016/j.atherosclerosis.2009.10.017.
39. Lee SJ, Thien Quach CH, Jung KH, et al. Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-1alpha activation through Nox2-dependent reactive oxygen species generation. J Nucl Med. 2014;55(10):1699–705. doi:10.2967/jnumed.114.139428. This paper links three aspects of atherosclerosis: oxLDL uptake, hypoxia, and glucose uptake for glycolysis.
40. Shiraki T, Aoyama T, Yokoyama C, et al. LOX-1 plays an important role in ischemia-induced angiogenesis of limbs. PLoS One. 2014;9(12):e114542. doi:10.1371/journal.pone.0114542.
41. Gerald D, Berra E, Frapart YM, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004;118(6):781–94. doi:10.1016/j.cell.2004.08.025.
42. Shatrov VA, Sumbayev VV, Zhou J, Brune B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood. 2003;101(12):4847–9. doi:10.1182/blood-2002-09-2711.
43. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43–54.
44. Giannarelli C, Alique M, Rodriguez DT, et al. Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor signaling. Circulation. 2014;130(15):1274–86. doi:10.1161/CIRCULATIONAHA.114.006614.
45. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218(1):7–29. doi:10.1002/path.2518.
46. Bonello S, Zahringer C, BelAiba RS, et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 2007;27(4):755–61. doi:10.1161/01.ATV.0000258979.92828.bc.
47. Schmeisser A, Marquetant R, Illmer T, et al. The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis. 2005;178(1):83–94. doi:10.1016/j.atherosclerosis.2004.08.038.
48. Fu H, Luo F, Yang L, Wu W, Liu X. Hypoxia stimulates the expression of macrophage migration inhibitory factor in human vascular smooth muscle cells via HIF-1alpha dependent pathway. BMC Cell Biol. 2010;11:66. doi:10.1186/1471-2121-11-66.
49. Asplund A, Stillemark-Billton P, Larsson E, et al. Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology. 2010;20(1):33–40. doi:10.1093/glycob/cwp139.
50. Folco EJ, Sukhova GK, Quillard T, Libby P. Moderate hypoxia potentiates interleukin-1beta production in activated human macrophages. Circ Res. 2014;115(10):875–83. doi:10.1161/CIRCRESAHA.115.304437.
51. Wanschel A, Seibert T, Hewing B, et al. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler Thromb Vasc Biol. 2013;33(5):886–93. doi:10.1161/ATVBAHA.112.300941.
52. Crucet M, Wust SJ, Spielmann P, Luscher TF, Wenger RH, Matter CM. Hypoxia enhances lipid uptake in macrophages: role of the scavenger receptors Lox1, SRA, and CD36. Atherosclerosis. 2013;229(1):110–7. doi:10.1016/j.atherosclerosis.2013.04.034. This publication illustrates an example how hypoxia may promote the uptake of oxLDL into macrophages. This represents one of the multiple mechanisms by which hypoxia activates processes that lead to the growth of atherosclerotic plaques.
53. Gimm T, Wiese M, Teschemacher B, et al. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1. FASEB J. 2010;24(11):4443–58. doi:10.1096/fj.10-159806.
54. Fong GH. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med (Berl). 2009;87(6):549–60. doi:10.1007/s00109-009-0458-z.
55. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007;116(7):774–81. doi:10.1161/CIRCULATIONAHA.107.701516.
56. Niecknig H, Tug S, Reyes BD, Kirsch M, Fandrey J, Berchner-Pfannschmidt U. Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia. Free Radic Res. 2012;46(6):705–17. doi:10.3109/10715762.2012.669041.
57. Mateo J, Izquierdo-Garcia D, Badimon JJ, Fayad ZA, Fuster V. Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using (1)(8)F-fluoromisonidazole positron emission tomographic imaging. Circ Cardiovasc Imaging. 2014;7(2):312–20. doi:10.1161/CIRCIMAGING.113.001084.
58. Silvola JM, Saraste A, Forsback S, et al. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice. Arterioscler Thromb Vasc Biol. 2011;31(5):1011–5. doi:10.1161/ATVBAHA.110.221440.
59. Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014;11(8):443–57. doi:10.1038/nrcardio.2014.80.
60. Yamashita A, Zhao Y, Matsuura Y, et al. Increased metabolite levels of glycolysis and pentose phosphate pathway in rabbit atherosclerotic arteries and hypoxic macrophage. PLoS One. 2014;9(1):e86426. doi:10.1371/journal.pone.0086426.
61. Rosenbaum D, Millon A, Fayad ZA. Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep. 2012;14(5):429–37. doi:10.1007/s11883-012-0264-x.
62. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003;100(8):4736–41. doi:10.1073/pnas.0730843100.
63. Moulton KS. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol. 2006;17(5):548–55. doi:10.1097/01.mol.0000245261.71129.f0.
64. Sluimer JC, Kolodgie FD, Bijnens AP, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol. 2009;53(17):1517–27. doi:10.1016/j.jacc.2008.12.056.
65. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809–13. doi:10.1038/nature07424.
66. Tanaka K, Nagata D, Hirata Y, Tabata Y, Nagai R, Sata M. Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein E-deficient mice. Atherosclerosis. 2011;215(2):366–73. doi:10.1016/j.atherosclerosis.2011.01.016.
67. Nakano M, Fukumoto Y, Satoh K, et al. OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc Res. 2010;88(3):539–46. doi:10.1093/cvr/cvq211.
68. Inoue M, Ishida T, Yasuda T, et al. Endothelial cell-selective adhesion molecule modulates atherosclerosis through plaque angiogenesis and monocyte-endothelial interaction. Microvasc Res. 2010;80(2):179–87. doi:10.1016/j.mvr.2010.04.005.
69. Slevin M, Krupinski J, Badimon L. Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention. J Angiogenes Res. 2009;1:4. doi:10.1186/2040-2384-1-4.
70. Drinane M, Mollmark J, Zagorchev L, et al. The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res. 2009;104(3):337–45. doi:10.1161/CIRCRESAHA.108.184622.
71. Christoph M, Ibrahim K, Hesse K, et al. Local inhibition of hypoxia-inducible factor reduces neointima formation after arterial injury in ApoE-/- mice. Atherosclerosis. 2014;233(2):641–7. doi:10.1016/j.atherosclerosis.2014.01.048. This article directly demonstrates that atherosclerotic plaque growth can be inhibited by suppressing the expression of hypoxia-inducible factor in injured arterial wall tissues.
72. Zernecke A, Schober A, Bot I, et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005;96(7):784–91. doi:10.1161/01.RES.0000162100.52009.38.
73. Lucerna M, Zernecke A, de Nooijer R, et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood. 2007;109(1):122–9. doi:10.1182/blood-2006-07-031773.
74. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50(4):331–47. doi:10.1016/j.plipres.2011.04.002.
75. Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2002;106(21):2700–6.
76. Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014;34(8):1731–8. doi:10.1161/ATVBAHA.114.303887.
77. Kiyan Y, Tkachuk S, Hilfiker-Kleiner D, Haller H, Fuhrman B, Dumler I. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. J Mol Cell Cardiol. 2014;66:72–82. 10.1016/j.yjmcc.2013.11.005.
78. Jeney V, Balla G, Balla J. Red blood cell, hemoglobin and heme in the progression of atherosclerosis. Front Physiol. 2014;5:379. doi:10.3389/fphys.2014.00379.
79. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25(10):2054–61. doi:10.1161/01.ATV.0000178991.71605.18.
80. Roiniotis J, Dinh H, Masendycz P, et al. Hypoxia prolongs monocyte/macrophage survival and enhanced glycolysis is associated with their maturation under aerobic conditions. J Immunol. 2009;182(12):7974–81. doi:10.4049/jimmunol.0804216.
81. Leppanen O, Bjornheden T, Evaldsson M, Boren J, Wiklund O, Levin M. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 2006;188(2):323–30. doi:10.1016/j.atherosclerosis.2005.11.017.
82. Wang Y, Zhou Y, He L, et al. Gene delivery of soluble vascular endothelial growth factor receptor-1 (sFlt-1) inhibits intra-plaque angiogenesis and suppresses development of atherosclerotic plaque. Clin Exp Med. 2011;11(2):113–21. doi:10.1007/s10238-010-0112-7.
83. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99(13):1726–32.
84. Qiao Y, Zhang PJ, Lu XT, et al. Panax notoginseng saponins inhibits atherosclerotic plaque angiogenesis by down-regulating vascular endothelial growth factor and nicotinamide adenine dinucleotide phosphate oxidase subunit 4 expression. Chin J Integr Med. 2014. doi:10.1007/s11655-014-1832-4.
85. Hauer AD, Habets KL, van Wanrooij EJ, et al. Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis. 2009;204(2):365–71. doi:10.1016/j.atherosclerosis.2008.09.039.
86. Hauer AD, van Puijvelde GH, Peterse N, et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(9):2050–7. doi:10.1161/ATVBAHA.107.143743.